LifeSci Acquisition II Corp. (Nasdaq:LSAQ) popped some 5% Friday after announcing plans to take drug-trials platform Science 37 public through a SPAC deal at about a $1.1 billion valuation.
Read More
LifeSci Acquisition II Corp. (Nasdaq:LSAQ) popped some 5% Friday after announcing plans to take drug-trials platform Science 37 public through a SPAC deal at about a $1.1 billion valuation.
Read More
